Corcept Therapeutics Incorporated (NASDAQ:CORT) shares surged Thursday following a second-quarter earnings beat.
What To Know: Corcept reported quarterly earnings of 25 cents per share which beat the analyst consensus estimate of 15 cents. The company also reported quarterly sales of $117.72 million which beat the analyst consensus estimate of $109.71 million, a 13.86% increase over sales of $103.39 million the same period last year.
On Thursday, the company had its price target raised by three analysts.
- HC Wainwright & Co. analyst Swayampakula Ramakanth maintained Corcept Therapeutics with a Buy and raised the price target from $30 to $32.
- Truist Securities analyst Gregory Fraser maintained Corcept Therapeutics with a Hold and raised the price target from $26 to $29.
- Piper Sandler analyst David Amsellem maintained Corcept Therapeutics with a Overweight and raised the price target from $27 to $31.
Related Link: Why Is Schrödinger Stock Tumbling Today?
CORT Price Action: Shares of CORT were up 25.5% at $31.38 at the time of publication, according to Benzinga Pro.
Image by Steve Buissinne from Pixabay
